SEE Question

Abstract

Listen

Translate article

Article| September 2022 SEE Question ASA Monitor September 2022, Vol. 86, 11. https://doi.org/10.1097/01.ASM.0000874208.64950.8b Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn MailTo Cite Icon Cite Get Permissions Search Site Citation SEE Question. ASA Monitor 2022; 86:11 doi: https://doi.org/10.1097/01.ASM.0000874208.64950.8b Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll PublicationsASA Monitor Search Advanced Search Topics: atrial fibrillation, blood transfusion, deep vein thrombosis, hemorrhage, ischemic stroke, kidney diseases, knee replacement arthroplasty, renal failure, acute, seizures, venous thromboembolism You are completing a preoperative evaluation of a 66-year-old woman with a history of deep vein thrombosis who is scheduled for total knee arthroplasty. Based on a recent study, which of the following is the MOST likely outcome for this patient if you administer tranexamic acid (TXA) during the procedure, compared with a similar patient who does not receive TXA? The antifibrinolytic agent TXA is widely used in total hip and knee arthroplasties because of its proven benefit in reducing blood loss. However, there is some concern that TXA may increase the risk of thromboembolic complications, renal dysfunction, or seizure, especially in patients with known risk factors for these complications. A recent retrospective cohort study sought to evaluate the association between the use of TXA and the risk of blood transfusions and complications when used in high-risk patients. Complications were evaluated as the composite of new-onset venous thromboembolism (VTE), myocardial... You do not currently have access to this content.